Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Afqlir 40 mg/ml Solution for injection in pre-filled syringe {equilateral_black_triangle}

Active Ingredient:
aflibercept
Company:  
Sandoz Limited See contact details
ATC code: 
S01LA05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Risk Materials Letters to HCPs Audio/Video
{arrow_left}
{arrow_right}
AFQLIR WAMD Patient Guide - Audio Version

Your guide to Afqlir- for the treatment of neovascular (wet) age-related macular degeneration (AMD)

AFQLIR DMO Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to diabetic macular oedema (DMO)

AFQLIR BRVO Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

AFQLIR CRVO Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)

AFQLIR CNV Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Sandoz Limited
Company image
Address
Maxis 1, Western Road, Bracknell, RG12 1RF, UK
WWW
http://www.sandoz.uk.com
WWW
https://pvi1j.solutions.iqvia.com
Telephone
+44 (0) 1276 698020
Medical Information Direct Line
+44 (0)1276 698 101
Medical Information e-mail
[email protected]
Adverse event reporting email
[email protected]
Customer Care direct line
+44 (0)1276 698020
E-mail
[email protected]
E-mail
[email protected]